Oral composition for inhibiting rise in blood glucose level and oral composition for inhibiting increase in blood triglyceride

Abstract

To provide oral compositions that are taken with a meal to exhibit high effects of inhibiting rise in a blood glucose level and increase in blood triglyceride.SOLUTION: The present invention discloses an oral composition for inhibiting rise in a blood glucose level that contains Terminalia bellirica and is taken with a meal. The present invention also discloses an oral composition for inhibiting increase in blood triglyceride that contains Terminalia bellirica and is taken with a meal.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to an oral composition containing Terminalia bellirica for suppressing an increase in blood glucose level, and an oral composition containing Terminalia bellirica for suppressing an increase in blood neutral fat level. [Background technology]

[0002] In recent years, with the rise in health consciousness, there is a strong demand for further improvements in health and beauty effects, and functional materials with multiple effects from one ingredient are attracting attention. For example, it is known that resistant dextrin has an intestinal regulation effect and a blood sugar level adjustment effect (Patent Document 1). However, in order to achieve the desired effect using resistant dextrin, a large amount must be ingested, and there is a problem that the method of ingestion and the form in which it can be ingested are limited. [Prior art documents] [Non-patent literature]

[0003] [Patent Document 1] JP 2005-287454 A Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide an oral composition having excellent effects of suppressing an increase in blood glucose level, suppressing sugar absorption, suppressing an increase in blood neutral fat level, and suppressing fat absorption. [Means for solving the problem]

[0005] In order to solve the above problems, the applicant has conducted extensive research into various substances and has surprisingly found that a composition containing Terminalia bellirica can be taken with a meal to provide excellent suppressive effects on blood glucose levels and blood neutral fat levels. The present invention has been completed based on this finding.

[0006] The outline of the present invention is as follows. <1> An oral composition for suppressing blood sugar level increase, comprising Terminalia bellirica, and characterized in that the oral composition is ingested with a meal. <2> An oral composition for suppressing an increase in blood neutral fat levels, comprising Terminalia bellirica, the oral composition being characterized in that it is ingested with meals. <3> An oral composition for suppressing an increase in blood glucose level and an increase in blood triglycerides, characterized in that it contains Terminalia bellirica, and is taken with a meal. <4> An oral composition for inhibiting sugar absorption, comprising Terminalia bellirica, the oral composition being characterized in that it is ingested with a meal. <5> An oral composition for inhibiting fat absorption, comprising Terminalia bellirica, the composition being characterized in that it is ingested with a meal. <6> An oral composition for inhibiting the absorption of sugar and fat, comprising Terminalia bellirica, the oral composition being characterized in that it is taken with a meal. <7> A method for suppressing blood sugar level rise using Terminalia bellirica as an active ingredient, characterized by ingesting the drug together with meals. <8> A method for suppressing an increase in blood triglycerides using Terminalia bellirica as an active ingredient, characterized by taking the drug together with meals. <9> A method for suppressing an increase in blood sugar levels and a method for suppressing an increase in blood triglycerides, characterized in that Terminalia bellirica is used as an active ingredient, and the method is characterized in that it is taken together with meals. <10> A method for inhibiting sugar absorption using Terminalia bellirica as an active ingredient, characterized by taking the drug together with meals. <11> A method for inhibiting fat absorption using Terminalia bellirica as an active ingredient, characterized by taking the drug together with meals. <12> A method for inhibiting the absorption of sugar and fat, characterized in that Terminalia bellirica is used as an active ingredient, and is taken with meals. Effect of the Invention

[0007] According to the present invention, an oral composition containing Terminalia bellirica can be provided that exhibits excellent blood glucose level increase suppression effects and sugar absorption suppression effects when taken with a meal. Also, according to the present invention, an oral composition containing Terminalia bellirica can be provided that exhibits excellent blood neutral fat increase suppression effects and fat absorption suppression effects when taken with a meal.

[0008] The present invention will be described in detail below.

[0009] [1. Terminalia belerica] Terminalia belliricca is a broad-leaved tree of the genus Terminalia in the family Combretaceae. In the present invention, any part of the tree may be used, but parts other than the seeds are preferred, and parts other than the seeds of the fruit (the peel and flesh) are more preferred from the viewpoints of the blood glucose level increase inhibitory effect, sugar absorption inhibitory effect, blood neutral fat increase inhibitory effect, and fat absorption inhibitory effect.

[0010] The Terminalia bellirica of the present invention can be used in the form of crushed matter, juice, extract, etc. Examples of crushed matter include powder and granules. The juice and extract may be in liquid form, but can also be used as a paste or dry powder. When making it into a paste or dry powder, it may be produced by using only the substance itself, or may be processed together with an excipient. The extract can be obtained by extraction using a suitable solvent, and examples of the solvent that can be used include water, methanol, ethanol, isopropanol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, acetic acid, ethyl acetate, diethyl ether, hexane, or a mixed solvent thereof. In the present invention, it is preferable to use water, methanol, ethanol, or a mixed solvent thereof in order to effectively exert the blood glucose level increase inhibitory effect, sugar absorption inhibitory effect, blood neutral fat increase inhibitory effect, and fat absorption inhibitory effect. The temperature during extraction can be appropriately adjusted from room temperature to a temperature below the boiling point of the extraction solvent. In the present invention, a commercially available product can be used.

[0011] The content of Terminalia bellirica in the oral composition of the present invention is not particularly limited as long as it is an amount that has the effect of inhibiting an increase in blood glucose level, sugar absorption, and blood triglyceride levels, as well as fat absorption, and is, for example, preferably 0.005% by mass or more and 80% by mass or less, more preferably 0.01% by mass or more and 50% by mass or less, and particularly preferably 0.05% by mass or more and 30% by mass or less.

[0012] In the present invention, it is preferable to contain gallic acid or its salt derived from Terminalia bellirica. The content of gallic acid or its salt in the oral composition of the present invention is preferably 0.0001% by mass or more in the composition, more preferably 0.0005% by mass or more, and particularly preferably 0.001% by mass or more. In addition, the content of gallic acid or its salt in the composition is preferably 30% by mass or less, more preferably 20% by mass or less, and particularly preferably 10% by mass or less.

[0013] The content of gallic acid or its salt in the oral composition of the present invention can be measured by a commonly known analytical method for gallic acid or its salt that is suitable for the condition of the sample to be measured. For example, it can be analyzed by liquid chromatography. In addition, when measuring, appropriate treatment may be performed as necessary, such as removing impurities in the sample to match the separation ability of the device.

[0014] 2. Oral Composition The oral composition of the present invention contains Terminalia bellirica and is characterized in that it is ingested with a meal. By ingesting the composition with a meal, the effects of suppressing an increase in blood glucose level, sugar absorption, an increase in blood neutral fat, and fat absorption are improved.

[0015] The form of the oral composition of the present invention is not particularly limited, and can be any form.For example, forms suitable for oral use, specifically, powder, granule, tablet, liquid, drink, gel, paste, capsule such as hard capsule or soft capsule, caplet, chewable, etc., can be mentioned, and various excipients, binders, lubricants, stabilizers, diluents, bulking agents, thickeners, gelling agents, emulsifiers, colorants, flavors, sweeteners, additives, etc. can be blended according to the form used.From the viewpoint of stability and ease of intake at the same time as meals, the oral composition of the present invention is preferably powder, granule, granule, tablet, chewable, capsule, more preferably tablet, powder.

[0016] The oral composition of the present invention may contain only Terminalia bellirica, or may contain other ingredients in addition to these two ingredients. The other ingredients are not limited as long as they are normally used as foods, and examples thereof include nutritional ingredients such as vitamins and minerals, plant-derived ingredients, animal-derived ingredients, functional sugars, polypeptides, vitamins, and fungi such as lactic acid bacteria, bifidobacteria, and butyric acid bacteria. From the viewpoint of suppressing an increase in blood glucose level, suppressing an increase in sugar absorption, suppressing an increase in blood neutral fat, and suppressing fat absorption, examples thereof include vitamins such as water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, vitamin C, vitamin P) and oil-soluble vitamins (vitamins A, D, E, K); minerals such as magnesium, phosphorus, zinc, and iron; sulfur-containing compounds contained in taurine, garlic, etc.; flavanoids or flavonoids such as hesperidin and quercetin; proteins such as collagen; peptides; amino acids; animal fats and oils; vegetable fats and oils; and crushed products or extracts of animals and plants.

[0017] The daily intake of the oral composition of the present invention is not particularly limited, and can be appropriately set depending on the mode of use and the content of use by the user. For example, based on the weight of the user, it is 0.01 to 160 g / 60 kg, preferably 0.05 to 80 g / 60 kg, and from the viewpoint of the blood glucose level increase suppression effect, the sugar absorption suppression effect, the blood neutral fat increase suppression effect, and the fat absorption suppression effect, it is more preferably 0.1 to 40 g / 60 kg. The amount of the oral composition of the present invention used once is also not particularly limited, and for example, based on the weight of the user, it is 0.005 to 160 g / 60 kg, preferably 0.01 to 80 g / 60 kg, and from the viewpoint of the blood glucose level increase suppression effect, the sugar absorption suppression effect, the blood neutral fat increase suppression effect, and the fat absorption suppression effect, it is more preferably 0.02 to 40 g / 60 kg. In addition, when the intake form is a beverage, it is the solid content (amount excluding water) in the beverage.

[0018] The oral composition of the present invention can be used, for example, as a medicine (including quasi-drugs), so-called health foods such as functional foods whose efficacy has been approved by a designated organization, such as foods for specified health uses, foods with nutritional functions, and foods with functional claims, as well as general foods, food additives, feed, etc.

[0019] The oral composition of the present invention can be used as a composition for suppressing an increase in blood glucose level and a composition for suppressing sugar absorption. Such a composition for suppressing an increase in blood glucose level and a composition for suppressing sugar absorption are not particularly limited as long as they contain Terminalia bellirica and can be distinguished from other products as a product in terms of being used to suppress an increase in blood glucose level and suppress the absorption of sugar. For example, the present invention includes a product that displays the function of suppressing an increase in blood glucose level and suppressing the absorption of sugar on the main body, packaging, instructions, or advertising material of the product according to the present invention. The composition for suppressing an increase in blood glucose level and a composition for suppressing sugar absorption of the present invention are not limited to those in which Terminalia bellirica is displayed as an active ingredient for suppressing an increase in blood glucose level and suppressing sugar absorption on the packaging of the product, and may be one in which the active ingredient is not specified.

[0020] Specifically, examples of the composition for inhibiting an increase in blood glucose level and the composition for inhibiting sugar absorption of the present invention include so-called health foods such as pharmaceuticals (including quasi-drugs) and functional foods such as specified health foods, nutritional functional foods, and functional food products whose efficacy has been approved by designated organizations. Examples of so-called health foods include those labeled with claims such as "for those who are starting to worry about their blood glucose levels," "for those who are concerned about their (post-meal) blood glucose levels," "gentle the rise in blood glucose levels," "gentle sugar absorption," "suppress sugar absorption," and "suppress blood glucose levels."

[0021] In addition, the oral composition of the present invention can be used as a composition for suppressing the rise in neutral fat in blood and a composition for suppressing fat absorption. Such a composition for suppressing the rise in neutral fat in blood and a composition for suppressing fat absorption are not particularly limited as long as they contain Terminalia bellirica and can be distinguished from other products as a product in terms of being used to suppress the rise in neutral fat in blood and to suppress the absorption of fat. For example, the present invention includes a product that displays the function of suppressing the rise in neutral fat in blood and the absorption of fat on the main body, packaging, instructions, or advertising material of the product according to the present invention. The composition for suppressing the rise in neutral fat in blood and a composition for suppressing fat absorption of the present invention are not limited to those that display Terminalia bellirica as an active ingredient for suppressing the rise in neutral fat in blood and the absorption of fat on the packaging of the product, and may be one that does not specify the active ingredient.

[0022] Specifically, examples of the composition of the present invention for inhibiting an increase in blood neutral fat levels and a composition for inhibiting fat absorption include so-called health foods such as pharmaceuticals (including quasi-drugs) and functional foods such as specified health foods, nutritional functional foods, and functional food products whose efficacy has been approved by designated organizations. Examples of so-called health foods include those labeled with claims such as "suppresses the increase in neutral fat levels," "for those concerned about neutral fat levels," "suppresses fat absorption," "gentles the increase in neutral fat levels," and "for those with high neutral fat levels."

[0023] The packaging form of the oral composition of the present invention is not particularly limited and can be appropriately selected depending on the dosage form, etc., and examples thereof include blister packs such as PTPs; strip packaging; heat seals; aluminum pouches; film packaging using plastics, synthetic resins, etc.; glass containers such as vials; and plastic containers such as ampoules. EXAMPLES

[0024] The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to these examples, and the present invention can take various forms as long as the object of the present invention can be achieved.

[0025] Ingestion of a composition containing Terminalia bellirica suppresses increases in blood glucose levels and blood neutral fat levels (1) Test substance Example 1: Terminalia bellirica extract (manufactured by Toyo Shinyaku Co., Ltd.) was dissolved in 100 mL of water so that the gallic acid content was 20.8 mg. Comparative Example 1: The Terminalia bellirica extract in Example 1 was replaced with caramel coloring (manufactured by Senba Toka Kogyo Co., Ltd.), and a coloring equivalent to that in Example 1 was used. (2) Blood glucose rise inhibition test and blood neutral fat rise inhibition test The test substance of Example 1 or Comparative Example 1 was prepared in a paper cup with a lid that prevented the contents from being seen, and 19 subjects (9 adult males, 10 adult females, average age 34.5 years) ingested it at the same time as the challenge food. The challenge foods used were ramen noodles and braised pork that had been prepared and heated. To ensure consistent challenge conditions, the challenge foods were ingested over a period of 25 minutes. The nutritional components of the challenge foods are shown in Table 1.

[0026] [Table 1]

[0027] Before, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes, and 240 minutes after ingestion of the test food and the challenge food, the subjects were asked to draw blood using a self-blood sampling device (a blood sampling puncture device, Gentlet (Sanwa Kagaku Kenkyusho) and a Gentlet needle (Sanwa Kagaku Kenkyusho)), and the blood was used to measure blood glucose and blood triglycerides. Blood glucose level: Before ingestion, 30 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion were measured using Glutest Eye (Sanwa Kagaku Kenkyusho) and Glutest Neo Sensor (Sanwa Kagaku Kenkyusho). The blood glucose level before ingestion was used as the base line, and the difference in blood glucose level 30 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion was calculated. In addition, the area under the blood concentration curve (iAUC) was calculated based on the obtained results. The results are shown in Table 2. Blood triglycerides: Before ingestion, 120 minutes, 180 minutes, and 240 minutes after ingestion were measured using Cobas B101 (Roche Diagnostics) and Cobas B101 lipid measurement reagent disk (Roche Diagnostics). The difference in blood triglyceride measurements 120 minutes, 180 minutes, and 240 minutes after ingestion was calculated based on the results before ingestion. In addition, the area under the blood concentration curve (iAUC) was calculated based on the results obtained. The results are shown in Table 3.

[0028] [Table 2]

[0029] [Table 3]

[0030] When Example 1 was taken with a meal, blood glucose levels were significantly lowered 60 minutes, 90 minutes, and 120 minutes after ingestion compared to Comparative Example 1. Furthermore, when Example 1 was taken with a meal, blood neutral fat levels were significantly lowered 120 minutes and 180 minutes after ingestion when the test food was taken compared to when the control food was taken, and low values ​​were maintained even after 240 minutes.

[0031] A significant decrease was observed in the blood glucose iAUC when taking Example 1 compared to the blood glucose iAUC when taking Comparative Example 1. Similarly, a significant decrease was observed in the blood neutral fat iAUC when taking Example 1 compared to the blood neutral fat iAUC when taking Comparative Example 1. Generally, AUC is used as a method for measuring the amount of absorption, and it was found that the absorption of sugar and fat contained in the meal is suppressed by taking the composition of Example 1 together with a meal.

[0032] From the above, it is understood that the oral composition containing Terminalia bellirica is taken with a meal to show excellent blood glucose level rise suppression effect and sugar absorption suppression effect. In addition, it is understood that the oral composition containing Terminalia bellirica is taken with a meal to show excellent blood neutral fat rise suppression effect and fat absorption suppression effect.

[0033] Example 2 Tablets (250 mg) consisting of the following ingredients were manufactured. By taking the obtained tablets, two tablets per time, three times a day with meals, excellent effects of suppressing increases in blood glucose level, sugar absorption, increases in blood neutral fat levels, and fat absorption can be obtained.

[0034] [Table 4]

[0035] Example 3 A liquid beverage containing the following ingredients was manufactured. By ingesting the resulting liquid beverage three times a day with meals (100 ml each time), it is possible to obtain excellent effects of suppressing increases in blood glucose levels, sugar absorption, blood neutral fat levels, and fat absorption.

[0036] [Table 5]

[0037] Example 4 Granules containing the following ingredients were manufactured. By dissolving 3 g of the obtained granules in 100 ml of water and taking them three times a day with meals, excellent effects of suppressing increases in blood glucose levels, sugar absorption, blood neutral fat levels, and fat absorption can be obtained.

[0038] [Table 6]

[0039] Example 5 Granules containing the following ingredients were manufactured and 200 mg was enclosed in a capsule. By taking two capsules three times a day with meals, the resulting capsules have excellent effects of suppressing increases in blood glucose levels, sugar absorption, blood neutral fat levels, and fat absorption.

[0040] [Table 7] [Industrial Applicability]

[0041] INDUSTRIAL APPLICABILITY The oral composition of the present invention has excellent effects of suppressing an increase in blood glucose level, sugar absorption, blood neutral fat level, and fat absorption when taken with a meal, and is therefore highly industrially useful.

Claims

1. An oral composition for suppressing blood sugar level increase, comprising Terminalia bellirica, and characterized in that the oral composition is ingested with a meal.

2. An oral composition for suppressing an increase in blood neutral fat levels, comprising Terminalia bellirica, the oral composition being characterized in that it is ingested with meals.

3. An oral composition for inhibiting sugar absorption, comprising Terminalia bellirica, the oral composition being characterized in that it is ingested with a meal.

4. An oral composition for inhibiting fat absorption, comprising Terminalia bellirica, the composition being characterized in that it is ingested with a meal.

Images